Track market-moving stories before they get noisy

In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo

Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes.1 Through its proven benefit in weight loss and its ability to improve certain cardiovascular risk factors like blood sugar, blood pressure and cholesterol, Foundayo may be a meaningful treatment option for the more than 100 million U.S. adults living with obesity.2 The findings of these analyses were published in Diabetes, Obesity and Metabolism.

"For many people living with obesity or overweight, the concern isn't just what the scale says today, it's whether their future could include type 2 diabetes or heart disease," said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. "These additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss. We've also seen evidence that treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes, can meaningfully lower healthcare costs.3,4,5 That gives us real optimism about what long-term Foundayo use could mean, both for patients and for the broader healthcare system."

In these analyses, modeling showed that Foundayo was associated with clinically meaningful improvements in predicted 10-year risk of type 2 diabetes and cardiovascular disease across all three doses.6 At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed an estimated 45.0%, 50.0% and 57.0% reduction, respectively, in predicted type 2 diabetes risk versus placebo.7,8 Participants taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo.

ATTAIN-1 Post-Hoc Analyses: Change in Predicted 10-Year Cardiometabolic Risk at 72 Weeks

Foundayo
5.5 mg

Foundayo
9 mg

Foundayo
17.2 mg

Placebo

Type 2 diabetes riski

Predicted 10-year type 2
diabetes risk at baseline

16.4 %

16.0 %

17.1 %

17.3 %

Change in predicted 10-year
type 2 diabetes risk at 72
weeks

-8.0 %

-8.8 %

-9.8 %

-1.7 %

Estimated type 2 diabetes risk
reduction vs. placeboii

45%

(HR = 0.55)

(95% CI 0.52, 0.60)

50%

(HR = 0.50)

(95% CI 0.47, 0.54)

57%

(HR = 0.43)

(95% CI 0.40, 0.47)

–

Cardiovascular disease riskiii

Predicted 10-year
cardiovascular disease risk at
baseline

8.5 %

8.5 %

8.7 %

8.9 %

Change in predicted 10-year
cardiovascular disease risk at
72 weeks

-0.6 %

-0.7 %

-1.0 %

0.6 %

Estimated cardiovascular
disease risk reduction vs.
placeboii

13%

(HR = 0.87)

(95% CI 0.83, 0.90)

15%

(HR = 0.85)

(95% CI 0.82, 0.89)

18%

(HR = 0.82)

(95% CI 0.79, 0.86)

–

iType 2 diabetes risk was estimated using the Cardiometabolic Disease Staging (CMDS) risk engine.

iiEstimated risk reduction versus placebo is approximated based on the model-based hazard ratio (HR); placebo was the reference group. 

iiiCardiovascular disease risk was estimated using the BMI-based Framingham risk engine. 

About Foundayo
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and the ATTAIN clinical trial program  
ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial is the first Phase 3 study of this patient population in which treatment was evaluated as an adjunct to exercise and a balanced, healthy diet rather than a reduced-calorie diet. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan in a 3:3:3:4 ratio to receive either 5.5 mg, 9 mg or 17.2 mg Foundayo or placebo. The primary objective of the study was to demonstrate that Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight.

All participants in the Foundayo treatment arms started the study at a dose of Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). The trial was conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.

The ATTAIN Phase 3 global clinical development program for orforglipron enrolled more than 4,500 people with obesity or overweight across two global registration trials (ATTAIN-1 & ATTAIN-2).

Endnotes and References

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138. Centers for Disease Control and Prevention. Adult Obesity Facts. https://www.cdc.gov/obesity/adult-obesity-facts/index.html. Bjornson AM, Szabo SM, Donato BMK, Gardner M, Kuti E. Costs of obesity, obesity-related complications, and weight loss in the United States: A systematic literature review. J Manag Care Spec Pharm. 2025;31(9):851-861. Xue J, Anderson J, Huang A, Gou R, Sun H, Zhao J, Allende C, Hua H, Hohlbauch A, Chinthammit C. Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee-For-Service Beneficiaries. Diabetes Obes Metab. 2026. Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. D'Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. Guo F, Garvey WT. Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes. The Journal of Clinical Endocrinology & Metabolism. 2015;100(10):3871-7. Wilkinson L, Yi N, Mehta T, Judd S, Garvey WT. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: a nationwide cohort and modeling study. PLoS medicine. 2020;17(8):e1003232. U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:
❑  Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑  Do you have a history of diabetic retinopathy?
❑  Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑  Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑  Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑  Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo™ is a trademark of Eli Lilly and Company.

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed.  You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell yourhealthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.  If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly   
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

Cautionary Statement Regarding Forward-Looking Statements  
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a potential treatment for adults with obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.  

SOURCE Eli Lilly and Company

Binance, the world’s leading cryptocurrency exchange by trading volume, has completed its latest scheduled Terra Luna Classic (LUNC) token burn. This round saw more than 334 million LUNC removed from circulation, a move that extends the company’s ongoing commitment to deflationary measures for the blockchain’s native coin.

Latest burn and supply outlookOn October 1, Binance executed the destruction of 334,879,422.009852 Terra Luna Classic tokens. These tokens were sent to a designated burn address, rendering them permanently ineligible to re-enter circulation.

According to official on-chain data, Binance has now burned more than 88 billion LUNC tokens to date, consistently reducing overall supply. The most recent figures show that the circulating supply now stands at approximately 5.51 trillion LUNC.

The cumulative LUNC burned across all participants has reached 460,108,314,222. Despite these extensive efforts, most analysts observed that the recent burn had little immediate impact on the trading price of LUNC or market momentum.

MetricValueLatest burn (October 1)334,879,422 LUNCTotal Binance burns (to date)88 billion LUNCTotal LUNC burned (all sources)460.1 billion LUNCCurrent circulating supply5.51 trillion LUNC24-hour trading volumeBelow $10 millionLow demand and technical barriersCrypto analysts noted on X that LUNC’s price action remains subdued, with daily trading volume on spot markets falling below $10 million. This lack of clear buying interest has muted any deflationary effect of the burns in terms of price appreciation.

LUNC’s trading price now hovers at $0.000052, sitting well beneath key trend lines such as the Double Exponential Moving Average (Double EMA) and the Smoothed Moving Average (SMA).

The token’s last significant rally occurred in mid-May, when it briefly touched $0.00012. Since then, LUNC has trended lower, with technical analysis suggesting that breaching the current moving average resistance remains a challenge.

Despite these challenges, some market observers have identified a modest uptick in whale activity. The Chaikin Money Flow (CMF), a technical indicator that measures buying and selling pressure, has risen to 0.14 since the start of September, potentially signaling renewed accumulation by large holders.

Mini dictionary: Chaikin Money Flow (CMF) is a technical analysis indicator that combines price and volume data to assess buying and selling pressure over a given period, often used to identify potential trend reversals.

Market commentators highlighted that this pattern mirrors the build-up seen before the rally in late April and early May, though current subdued spot volumes make any near-term recovery uncertain.

Ongoing competition and outlookDespite Binance’s consistent LUNC burn program, the coin’s price has remained under pressure amid increased competition within the altcoin market. Analysts suggest that while deflation reduces supply, price movements largely depend on revived demand and broader market sentiment.

With active spot trading at a standstill and ongoing supply reduction efforts, Terra Luna Classic’s trajectory remains closely watched by the community as investors look for fresh catalysts to boost demand.

TL;DR: The OAT-Bund spread widened past 140.6bp, its widest since the 2012 eurozone debt crisis, as French 10-year yields surged to 4.935% while German Bund yields fell to 3.529%—a divergence pointing to a France-specific sovereign risk premium that EUR/CHF is now starting to transmit into FX.

Why This Matters Europe’s bond selloff has stopped being one trade. Investors are now separating France from Germany—and EUR/CHF is starting to reflect the same divide. When two countries share a currency and a central bank but their bond yields move in opposite directions, that is not a generic rates story; it is markets pricing one government’s fiscal credibility differently from another’s. For traders, that makes the spread itself, not the outright yield level, the cleanest signal of how far this repricing could run, and it gives EUR/CHF a specific technical path to watch for confirmation.

Currency Heat Map.

France Is Being Asked to Pay More for Fiscal Risk The immediate backdrop is France’s 2027 budget. Prime Minister Sebastien Lecornu’s government has presented a package targeting around EUR 54bn of savings, seeking to reduce the deficit from 5.4% of GDP in 2026 toward 5% next year. Measures include spending restraint and targeted tax changes, but the legislation now faces a difficult parliamentary process in a divided legislature and is likely to be amended substantially.

The bond-market mechanism is straightforward. When investors become less confident that a government can stabilise its deficit and debt trajectory, they demand a larger yield premium to hold that government’s debt. In France’s case, that premium is visible against Germany, whose Bund market serves as the Eurozone’s core benchmark.

That distinction matters because France and Germany share the same currency and the same ECB policy rate. A global rates shock can push both yields higher together. It does not easily explain French yields accelerating toward 5% while German yields fall. That is why the spread, rather than the outright OAT yield, is becoming the cleanest gauge of whether markets are escalating their concerns about France.

The French 10-year chart reinforces the severity of the move. Yield is well above the 4H 55 EMA near 4.616%, with RSI above 80 and MACD still positive. German yields, by contrast, have fallen back toward their 55 EMA near 3.535%, while RSI has slipped below 40 and momentum has rolled over. The technical picture is therefore telling the same story as the spread: French risk is accelerating while demand for German duration is returning.

Inflation Makes the Backdrop Harder, but Does Not Explain the Divergence Europe’s inflation backdrop is adding pressure, but it cannot by itself explain the France-Germany split. French national CPI accelerated from 2.4% to 3.0% y/y in September, while the comparable harmonised measure rose from 2.6% to 3.4%. Germany’s harmonised inflation also accelerated to 3.3%, with energy inflation reaching 14.9%. In France, energy inflation was even stronger at 21.2%.

That helps explain why European yields remain structurally elevated. Renewed energy pressure and the Middle East conflict have revived concerns about how quickly inflation can return sustainably toward target. But the common inflation shock actually makes the OAT-Bund divergence more informative: if inflation alone were driving Thursday’s bond move, French and German yields should be responding more similarly. Instead, Bunds rallied while OATs sold off.

Inflation is therefore an amplifier of France’s problem, not a complete explanation for it. The widening spread reflects the interaction of higher inflation risk, higher term premia and French fiscal uncertainty, a combination also highlighted by market strategists as the premium on French debt widened.

European Equities Add Context, but the Spread Carries the Cleaner Signal European equities sold off alongside the bond-market stress, with CAC 40, DAX and FTSE all under pressure. Yet the equity move is a noisier measure of French-specific risk. German and British shares are exposed to the same higher-energy, higher-yield environment even without France’s fiscal problem, which makes a broad European equity decline compatible with several different macro explanations.

Wall Street, meanwhile, managed to close modestly higher after the US 10-year Treasury yield retreated from its 5.34% intraday peak, with company-specific technology developments also providing support. The more useful hierarchy is therefore clear: OAT-Bund spread first. EUR/CHF second. Equities third. The first strips away much of the global-rates noise. The second shows whether FX traders are transmitting the same European risk discrimination into the Swiss franc.

140bp Is Now the Key Sovereign-Risk Test The spread itself is the most direct test of whether this develops into something more persistent. At around 140.6bp, investors are already demanding substantially more compensation to own French debt than German Bunds. Reuters had recorded the spread at 132.86bp on October 1, already its widest since the 2012 eurozone debt crisis. The subsequent move beyond 140bp therefore represents another meaningful extension.

From here, continued widening would strengthen the case that markets are making a structural adjustment to France’s risk premium, rather than simply reacting to a single difficult session. A stabilization around current levels would suggest investors are waiting for more clarity from the budget process. A meaningful reversal toward the 90–95bp area seen before the latest acceleration would weaken the argument that a durable repricing is underway.

That makes France’s parliamentary budget process the next hard domestic catalyst. The government has laid out the fiscal arithmetic; markets now need to judge how much of it can actually survive the legislative process.

ActionForex’s Technical View: EUR/CHF Is Starting to Transmit the Same Message FX is beginning to reflect the bond-market divergence. EUR/CHF has reversed sharply from 0.94850 to around 0.9340, falling back below its daily 55 EMA near 0.9371. Momentum has deteriorated with RSI below 40 and MACD rolling lower.

Franc strength has not been confined to Euro either—USD/CHF and GBP/CHF have also fallen, showing broader CHF demand. But EUR/CHF remains the more useful instrument for the French-risk thesis because it directly pits the common currency against Europe’s traditional low-risk funding currency.

Technically, however, the move remains at an early stage. The rise from 0.89790 to 0.94850 puts the 38.2% Fibonacci retracement at around 0.92917 and the 61.8% retracement at 0.91723. EUR/CHF has not yet reached the first level. That gives a useful hierarchy:

A hold above 0.92917, followed by a recovery, would keep the decline consistent with a relatively shallow correction within the broader advance from 0.89790. A sustained break below 0.92917 would strengthen the bearish case. A move toward 0.91723 would suggest a substantially deeper repricing and put the broader recovery from 0.89790 into question. But the bond spread must remain part of the confirmation. A EUR/CHF break below 0.92917 alongside another widening in OAT-Bund would provide a much cleaner signal that French fiscal risk is spreading through European assets. The same EUR/CHF break occurring while OAT-Bund stabilizes or narrows would be less convincing—it could instead reflect generic Euro weakness, broader CHF demand or positioning around US data.

NFP Can Blur the Signal Before France Gives the Next Answer Today’s US nonfarm payrolls release, with consensus around 90K, adds a major external complication. A large payroll surprise could dominate global rates, Dollar and risk sentiment, potentially obscuring the France-specific signal for several hours. That makes relative moves more useful than outright FX moves after the release.

The most informative configuration would be continued OAT-Bund widening accompanied by renewed EUR/CHF downside. That would suggest French risk is still driving the move even through the US data noise. If USD/CHF moves sharply after NFP while EUR/CHF remains relatively stable, the Dollar channel would be doing more of the work. If EUR/CHF continues falling while USD/CHF does not, the European risk signal becomes cleaner.

But NFP is ultimately an external interruption. France’s budget process remains the harder test. The market has already pushed the OAT-Bund spread beyond 140bp. EUR/CHF has begun to respond, but it has not yet broken its first major retracement level.

France and Germany still share a currency and a central bank. For now, their bond markets are increasingly pricing them as very different risks.

Key Takeaways The OAT-Bund spread has widened past 140.6bp, its widest since the 2012 eurozone debt crisis, as French yields rise and German yields fall simultaneously. The divergence points to a France-specific fiscal risk premium tied to Prime Minister Lecornu’s 2027 budget, not a generic eurozone rates move—inflation is running hot in both countries but cannot explain the split. EUR/CHF has reversed from 0.94850 to around 0.9340 but has not yet broken its first key retracement at 0.92917; a break there alongside continued spread-widening would be the cleanest confirmation signal. The recommended watch order is OAT-Bund spread first, EUR/CHF second, European equities third, since equities are a noisier read on French-specific risk. Today’s NFP release could temporarily obscure the France signal; watch whether EUR/CHF moves independently of USD/CHF to judge whether European risk, not the Dollar, is driving price action. Related Reading Sterling Broadens Gains as BoE Repricing Builds and GDP Confirms Resilience Dollar Index Completes Double Bottom, Targets 100.59 as Markets Look Beyond Fed’s 4.1% 2027 Median Gold Holds 4,113 Support, but 4,235 and 4,335 Still Block the Bull Case Stay ahead of Europe’s sovereign-risk divergence—subscribe to ActionForex’s daily market commentary for real-time technical and fundamental analysis.

ActionForex

ActionForex.com was set up back in 2004 with the aim to provide insightful analysis to forex traders, serving the trading community for two decades. We started providing only a daily and a mid-day report, now known as Action Insights. Gradually, we added a lot more in-house contents to the site. Technical Outlook section was expanded to cover more pairs. In addition to that, Top Movers, Heat Map, Pivot Point Charts and Pivot Meters, Action Bias and Volatility Charts, are tools used by traders from all over the world.

It's been a good year for most of the Magnificent Seven. As of this writing, Apple and Nvidia are both up over 23% in 2026, and even Microsoft, the smallest gainer, is up about 7%. Alphabet, Meta Platforms (META +0.10%), and Amazon land in between.

Then there's Tesla (TSLA -0.20%). At roughly $347 as of this writing, the electric-car maker's shares are down about 23% this year and about 29% off their record close of $489.88, set in December 2025.

It's the only one of the seven in the red.

The strange part, I think, is that Tesla's sales are rising again. The gap shows up further down the income statement.

Image source: Getty Images.

Is demand the problem?Not lately. Tesla delivered 480,126 vehicles in the second quarter, up 25% year over year and a sharp acceleration from 6% growth in the first quarter. This followed a tough 2025, when deliveries dropped around 9% to 1,636,129.

Tesla's second-quarter revenue climbed 26% year over year to about $28.2 billion, beating the latest-quarter growth rates for Apple (16%), Microsoft (18%), Amazon (20%), and Alphabet (24%).

Yes, some of that's a rebound from a poor 2025. But on sales alone, Tesla fits right in with the rest of the group.

Tesla's profits aren't keeping upShowing how little of that growth reaches the bottom line, Tesla's second-quarter operating income dropped 57% year over year to around $398 million. Its operating margin (the share of revenue left as operating profit) shrank to just 1.4%, down from 4.1% in the year-ago quarter, as operating expenses jumped 47%. Non-GAAP (adjusted) earnings per share dropped 18%. And in the first half of 2026, Tesla delivered 16% more vehicles than a year before but earned around the same operating income ($1.34 billion vs. $1.32 billion).

The other six look very different. Five of them raised operating income by double digits in their latest quarters, from 18% at Microsoft to 124% at Nvidia.

Even Amazon, which has the lowest margins among the six, kept about 14 cents of every sales dollar as operating profit. Tesla kept about 1.4 cents.

Meta's the exception. Its second-quarter operating income dropped 8%, hurt by $2.4 billion in legal charges and $1.18 billion in severance. But its operating margin was still 31%, and management expects full-year operating income to beat 2025's.

Spending firstSure, low margins might matter less if the payoff looked close. But Tesla expects capital expenditures of over $25 billion in 2026, due to its AI initiatives. With around $8.3 billion spent in the first half, that implies more than $16 billion in the second. Second-quarter free cash flow was already negative $1.1 billion. And on Sept. 29, Tesla signed $30 billion in new credit facilities, but it doesn't currently plan to tap them this year.

The projects this spending funds are still early. Tesla's Robotaxi service was live in seven major metro areas by its second-quarter update, and the steering-wheel-free Cybercab began giving rides to Robotaxi app users in a limited part of Austin in early September. But Tesla doesn't break out robotaxi revenue, so investors can't yet tell what the service makes.

Meanwhile, the stock already prices in a lot of success. Based on next year's expected earnings, Tesla's price-to-earnings ratio is around 155. Nvidia's stock, in comparison, costs about 15 times next fiscal year's expected earnings, even though its operating income more than doubled last quarter.

Premium Feature

Moneyball Superscore

64/100

Today's Change

(

-0.20

%) $

-0.70

Current Price

$

354.11

What can the delivery count add?Tesla hasn't given a date for its third-quarter delivery release. But its past two quarterly counts came out on the second day of a new quarter, so the next one may arrive within days.

A year ago, Tesla delivered a record 497,099 vehicles, so it probably needs another record just to show growth. Still, even a strong count can't settle what separates Tesla from the other six this year.

"Tesla vehicle deliveries and storage deployments represent only two measures of the Company's financial performance and should not be relied on as an indicator of quarterly financial results," the company wrote in its July 2 delivery report.

In the end, Tesla's 2026 problem isn't that customers quit buying its cars. It's that the business keeps very little of what it sells -- while spending heavily on projects that haven't paid off yet. At around 320 times the past year's earnings, I'd say Tesla stock's still too pricey for a company that kept 1.4 cents in operating profit on every sales dollar last quarter.

Netflix's (NFLX -2.49%) bad year got worse last month as signs continued to show that the company was losing ground to rival YouTube, and even co-CEO Ted Sarandos acknowledged that recent engagement trends have been disappointing.

At the Emmys last month, Netflix had its lowest-converting and weakest performance at the TV awards show in a decade, reflecting an underwhelming slate of original programming.

The stock finished September down 14%, according to data from S&P Global Market Intelligence.

As you can see from the chart below, the stock fell mostly steadily over the course of the month, reflecting souring forward expectations as the streamer struggles with engagement.

NFLX data by YCharts

What's going wrong at NetflixThere was no major company-specific news out on Netflix last month. Instead, there was a steady drumbeat of downbeat news items and negative analyst notes.

On Sept 18, Wells Fargo lowered its rating on Netflix from equal weight to underweight and slashed its price target from $80 to $57, predicting a weak original content slate in the second half of the year. It also forecast a 21% decline in hours watched for its top 100 original shows, which would represent a crisis at Netflix if true.

HSBC followed that up with its own downgrade from buy to hold, citing trends that show Netflix has lost significant viewer share to YouTube over the last year, as Netflix's share of viewing time in the U.S. fell by about one percentage point to 7.8%.

Netflix's disappointing showing at the Emmys also seemed to underscore its troubles, as it had its lowest Emmy conversion rate in a decade, winning 16 awards on 111 nominations. It finished behind both Apple TV and HBOMax, and Netflix was nearly shut out of top categories like major comedy and drama.

Toward the end of the month, co-CEO Ted Sarandos addressed the company's challenges, saying it is "not growing as fast as I want," and he cited headwinds related to its investments in live sports, which, on an ROI basis, perform poorly in terms of engagement. Nonetheless, live sports are good for signups and advertising, and the company expects to do more of it.

Image source: Netflix.

What's next for NetflixNetflix will report third-quarter earnings on Oct. 20, but the results are unlikely to kick-start a comeback, given Sarandos's own admission of weak growth.

However, there is an argument that Netflix has gotten too cheap at this point, trading down nearly 50% from its all-time high last year.

The company has dug out of holes like this before, and it likely only needs one or two hit shows to change the narrative. Meanwhile, its resilient business model and global presence should help overcome these challenges. While the stock could head lower in the short term, it still looks like a winner over the long term.

End-to-end service program combines fuel cell module performance guarantee with committed service response and resolution times, to enable transit operators to plan maintenance and fuel cell lifecycle costs.

, /PRNewswire/ -- Ballard Power Systems is launching the first-of-its-kind fuel cell lifecycle programme – Ballard Fleet360 – at APTA TRANSform & EXPO 2026 in Chicago.

Available with new FCmove®-HD+ module sales in North America, the program connects intelligent fuel cell data, tailored technical support, parts assurance, technician training and refurbishment options. Fleet360's FCcare+ coverage package provides a fuel cell module performance guarantee for power output up to 250,000 miles of fuel cell operation.

Ballard Fleet360 fuel cell lifecycle program "Transit operators want confidence in how their fuel cells perform today and as their fleets age," said Ralph Robinett, Chief Operating Officer of Ballard. "With Fleet360, we are backing our technology with a defined performance guarantee, supported by the information, parts and technical support maintenance teams need. This capability gives customers a clearer basis for planning fuel cell maintenance and lifecycle budgets, with performance commitments from Ballard."

Turning fuel cell data into maintenance decisions

At the center of Fleet360 is FCpulse, Ballard's digital platform for visibility into fuel cell health, performance and service-part trends. Its state of health dashboard helps maintenance teams proactively identify modules needing attention, prioritise investigations and prepare workshop resources. Its data visualizer access supports deeper technical investigation, while quarterly performance reports inform service and lifecycle planning.

Defined guarantees for module performance

The FCcare service package combines full parts coverage with commitments for response, spare part delivery and resolution, alongside FCpulse state of health dashboard access. The FCcare+ package adds a fuel cell module performance guarantee for power output power up to 250,000 miles of fuel cell operation. Guarantees and service commitments are defined by the package and agreement selected. Core+ refurbishment, Ballard Academy training and the full version of FCpulse are available alongside either package.

Service support built around fleet operations

The program is supported by Ballard's Remote Operations Centre in Vancouver, which coordinates triage, diagnostics and engineering escalation, together with expanded field service capability and US parts inventory in Bend, Oregon. The Ballard Academy builds customers' in-house maintenance capability and diagnostic skills, while Core+ connects stack condition assessment with refurbishment planning.

"Data creates value when it helps a maintenance team decide what to do next," Robinett added. "By connecting FCpulse insights with parts support, technical expertise and refurbishment planning, we can help operators prepare for maintenance and budget for the fuel cell module over its life. Our role is to give their teams the information and practical support to make those decisions with greater confidence."

Fleet360 builds on Ballard's experience across more than 186 million miles (300 million kilometers) of operational service and more than 3,000 fuel cell engines on the road. Today, Ballard has deployed nearly 330 fuel cell buses across North America, including over 225 buses in California and a fleet of more than 30 in Nevada.

Together, the market-leading FCmove® range of fuel cell engines and Ballard Fleet360 demonstrate Ballard's focus on the complete customer journey – from vehicle integration and deployment to reliable operation throughout the fleet lifecycle.

Ballard's presence at APTA EXPO 2026 also comes just weeks after the completion of its acquisition of GeoPura. The acquisition broadens Ballard's capabilities beyond fuel cell engines to include hydrogen production, logistics, refueling, and integrated Energy-as-a-Service solutions. These expanded capabilities strengthen Ballard's ability to support customers with the technology, services, and hydrogen solutions needed to deploy and operate zero-emission fleets at scale.

Meet Ballard at APTA EXPO 2026

Transit operators and bus manufacturers can meet Ballard's team at APTA EXPO 2026 to discuss Fleet360 coverage and service options. Visit us at Booth 462 from October 5-7.

About Ballard

Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) is a global leader in zero-emission hydrogen energy solutions and an integrated Energy-as-a-Service (EaaS) provider. Together, with its wholly owned subsidiary, GeoPura Ltd., Ballard delivers turnkey, vertically integrated hydrogen ecosystem solutions spanning hydrogen production, logistics, refuelling, zero-emission fuel cell engines, and stationary Hydrogen Power Units.

Ballard powers critical off-grid, stationary applications - including construction, events, film sets, healthcare, defense, temporary power infrastructure, and supplies fuel cell engines for heavy-duty mobility applications such as bus, rail, and marine. With an EaaS model, combined with cutting-edge technology across the hydrogen value chain, Ballard decarbonizes mission-critical operations worldwide. To learn more about Ballard, visit www.ballard.com.

Further Information

Sumit Kundu – Investor Relations, +1.604.360.3517 or [email protected]

SOURCE Ballard Power Systems Inc.

Nike is staring down its worst stock performance in decades while rivals steal its customers and its own earnings hide a financial lifeline most investors missed. LeBron James thinks he knows exactly where the brand went wrong.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

LeBron James still moves money for whoever he plays for. After he joined the Philadelphia 76ers, the team’s ticket sales on StubHub (NYSE:STUB | STUB Price Prediction) jumped 585%, and the Sixers drew 38% of all NBA ticket search traffic. Nike (NYSE:NKE) has paid him since 2003, and it heads into tonight’s earnings report in much worse shape.

Nike traded at $35.09 late Thursday. That leaves the stock down 43.46% year to date and 48.01% over the past 12 months. CNBC reported that Nike is on track for its worst year since 1993, the year Michael Jordan first retired.

LeBron’s Fix Goes Straight to What Nike Lost At the CNBC Sport x Boardroom Game Plan Summit on July 16, Boardroom’s Rich Kleiman asked James how Nike could recover:

“You’ve got to get back into the roots. You’ve got to get back to being out in the inner city, having runners. When I was coming up, you had people who were literally out in the communities talking to these younger generations, asking them what they like, what they don’t like.”

He ended with a warning:

“It was such a cool factor. So we can’t lose our cool.”

On Thursday, CNBC paired the clip with Wharton marketing professor Americus Reed, who argued that Nike leaned too hard on direct-to-consumer channels and celebrity deals while letting community relationships slip. A sellout shoe is a transaction; loyalty is separate. Pulling back from retail stores removed the emotion and storytelling that build deeper bonds with shoppers. Reed’s point: a brand “has to live and breathe within the community.”

Nike’s Recent Profits Lean on a Tariff Refund In its June 30 report, Nike posted revenue of $10.97 billion, down 1.1% from a year earlier. Diluted EPS came in at $0.72, but $0.52 of that came from a $986 million tariff-recovery benefit. Without the refund, full-year EPS would have been $1.58. Digital sales fell 12%, Greater China dropped 17% on a currency-neutral basis, and Converse sank 32%.

CEO Elliott Hill named the weakest spots:

“We know we’re not living up to our full potential, particularly in Nike Sportswear and Jordan Streetwear, where sell-through remains challenged.”

Sportswear and Jordan Streetwear make up about half of Nike’s revenue. Running is strongest, with five consecutive quarters of double-digit growth. Hill: “When we lead with sport, we win.”

Rivals Reed Named Are Taking Share Reed singled out Hoka and On Holding (NYSE:ONON) as the brands winning shoppers’ attention. On Holding grew Q2 2026 revenue 13.49%, or 21.6% in constant currency. Its gross margin reached 65.4%, and direct sales rose 26.0%. On Holding also signed Kylian Mbappé away from Nike as it moves into soccer. Co-CEO David Allemann described the strategy:

“We are proving that a brand can achieve global scale without compromising its premium brand positioning.”

At Deckers Outdoor (NYSE:DECK), Hoka’s net sales rose 7.7% to $703.50 million, and gross margin came in at 56.4%. Nike’s full-year gross margin, excluding the tariff benefit, was 40.8%.

What to Watch After the Bell Management guided for revenue to fall by a low to mid-single digits percentage. CFO Matt Friend said “profitability will bottom before sales” in China. Analysts are conservative: 25 rate the stock a hold, with a $45.63 price target. Watch whether sell-through improves in Sportswear and Jordan, and whether running’s momentum spreads to basketball. Hill warned that “progress will continue to be uneven.”

Data Sources CNBC: Wharton’s Americus Reed on Nike: Reed’s view on transactions versus loyalty, the effect of direct-to-consumer, and the worst-year-since-1993 comparison. Contact [email protected] for any questions or corrections.

The pilots of a ​Miami-based 21 Air cargo plane operating for Amazon.com that crashed in Miami last month killing ‌five people, were unaware of wind conditions, the National Transportation Safety Board said on Thursday.

The NTSB's preliminary report is the first detailed account of the September 6 crash and points to a series of likely failures — from excessive speed and unused braking systems to ​missing wind information from an air traffic controller — that may have led to one of the deadliest ​US runway accidents in years.

The 21 Air-operated cargo flight for Amazon Air, which is Amazon's ⁠cargo logistics network, overran a runway while landing at Miami International Airport and struck two vehicles on the ground. ​Amazon has since paused use of 21 Air.

The NTSB said a Federal Aviation Administration air traffic controller issued a ​landing clearance, but did not provide information on the wind as required by the FAA.

About four minutes before issuing the landing clearance, when asked by another flight for wind information, the controller stated winds were from 190° at 19 knots with gusts to 22 knots. The 21 ​Air flight was not on the radio frequency at the time, the NTSB said.

The FAA did not immediately comment.

The ​aircraft was a 32-year-old Boeing (BA.N) 767-300 freighter that had previously operated as a passenger jet for various airlines from 1994 to ‌2015.

The NTSB ⁠said the captain of the 21 Air-operated plane considered aborting the landing after the aircraft touched down, citing evidence from a flight data recorder.

The NTSB said the first officer cautioned the captain they were flying "too fast" just over a minute before touching down on the runway that they overran and made additional comments about the airplane’s excessive speed.

The ​NTSB said the captain did ​not verbally acknowledge all ⁠of the first officer's comments about speed. The NTSB said data showed the speed brakes remained stowed and the thrust reversers did not deploy during the landing.

The airplane touched ​down about 3,750 feet (1143 meter) past the start of the runway at a groundspeed ​of 160 knots (184mph).

The ⁠cargo plane was on its third flight of the day, coming from San Juan, Puerto Rico. It had flown from Cincinnati to Miami and from Miami to San Juan earlier before the crash.

Amazon said it remains committed to supporting the ⁠NTSB’s ongoing ​investigation.

21 Air said its "executive leadership team is actively engaged in managing operational ​risk and fostering a culture of accountability and continuous improvement."

The company added it is reviewing the NTSB preliminary report and "will take all appropriate ​action to improve our safety based on the facts as they are established.”

SummaryNike enters FY27 with worsening fundamentals: revenue shrinking, China collapsing, wholesale relying on costly retailer working capital, and margins at risk despite temporary logistics relief.Q1 FY27 shows accelerating deterioration: China is down 22%, Converse is down 28%, EPS reset 25% below expectations, and management is guiding high‑single‑digit revenue declines for the full year.Valuation remains stretched at 27x guided EPS, dividend payout hits 131%, $2B debt maturity looms, and multiple compression points to a clear path toward $30 or even $25.Looking for a helping hand in the market? Members of iREIT®+HOYA Capital get exclusive ideas and guidance to navigate any climate. Learn More » ozgurdonmaz/iStock Unreleased via Getty Images

Introduction Three months ago, I wrote that at a share price of $40 for Nike (NKE) still wasn't cheap. Entering its earnings report, the stock was down 15% to $35.21, its 52-week low. While the brand is surely valuable, I pointed out that the

8.48K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Caterpillar (CAT - Free Report) closed the most recent trading day at $826.35, moving +1.92% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.2%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, added 0.04%.

Heading into today, shares of the construction equipment company had gained 2.34% over the past month, outpacing the Industrial Products sector's loss of 0.74% and the S&P 500's loss of 0.35%.

The investment community will be closely monitoring the performance of Caterpillar in its forthcoming earnings report. The company is predicted to post an EPS of $6.95, indicating a 40.4% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.19 billion, indicating a 14.47% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $27.37 per share and a revenue of $79.37 billion, signifying shifts of +43.6% and +17.43%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for Caterpillar. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.09% higher. Caterpillar is currently sporting a Zacks Rank of #1 (Strong Buy).

Investors should also note Caterpillar's current valuation metrics, including its Forward P/E ratio of 29.62. This expresses a premium compared to the average Forward P/E of 17.81 of its industry.

It is also worth noting that CAT currently has a PEG ratio of 1.41. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Manufacturing - Construction and Mining industry currently had an average PEG ratio of 1.25 as of yesterday's close.

The Manufacturing - Construction and Mining industry is part of the Industrial Products sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 34% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

The divestment of a majority stake in a legacy business was the factor lifting Thomson Reuters (TRI +2.09%) stock above many others on Thursday. With that tailwind at its back, the business-focused media company's stock rose by more than 2% that trading session, on a day when the bellwether S&P 500 index only crept up by 0.2%.

Done dealThat morning, Thomson Reuters announced that it had closed the sale of a 51% stake in its global print unit. The buyers are what the company described as "capital accounts," advised by the veteran private equity firm KKR (KKR -0.07%).

Image source: Getty Images.

Following the sale, the newly named Westbridge Print will operate as a joint venture, with Thomson Reuters retaining a minority stake. Westbridge will concentrate on publications for legal and tax professionals. It will also offer commercial printing services for book publishers.

The move is an attempt to narrow Thomson Reuters' focus on next-generation, artificial intelligence (AI) solutions targeting industries it has served for years. Namely, these are the tax, audit, compliance, and legal fields.

The company did not provide any financial details of the transaction in its announcement. However, when originally divulging the sale in July, it said KKR would pay roughly $500 million.

Today's Change

(

2.09

%) $

2.03

Current Price

$

99.36

The future of specialty mediaThomson Reuters is clearly determined to push hard into next-generation offerings for its relatively affluent client base. This strategy depends on being tech-forward, so shedding large stakes in legacy operations like print media makes a great deal of sense.

So we should consider this to be good news from Thomson Reuters, and a sure sign that it's executing on an important objective.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends KKR. The Motley Fool recommends Thomson Reuters. The Motley Fool has a disclosure policy.

Expansion Recognizes the Strength of PECO’s Operating Platform while Generating Capital for PECO to Acquire Properties with Strong Growth Profiles  | Source: Phillips Edison & Company, Inc.

CINCINNATI , Oct. 01, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced an amended and restated joint venture partnership with Northwestern Mutual, one of the largest commercial real estate mortgage and equity investors in the U.S., which extends the term of the venture, Grocery Retail Partners I LLC (“GRP I”), by 10 years to 2036.

The expanded joint venture will acquire 13 high-quality, grocery-anchored shopping centers currently owned and operated by PECO across eight states. The portfolio is valued at approximately $377.5 million. Northwestern Mutual and PECO will retain approximately 86% and 14% interest in the joint venture, respectively. PECO will continue to provide leasing, asset management and property management services for the joint venture, in addition to earning recurring fees related to these services. The expansion creates incremental investment capacity for PECO to fund future acquisitions, development and redevelopment opportunities.

Jeff Edison, Chairman and Chief Executive Officer of PECO, stated: “Expanding our partnership with Northwestern Mutual, one of the country’s largest and most experienced commercial real estate investors, demonstrates continued institutional demand for high-quality, grocery-anchored shopping centers.”

The 13 assets are located in suburban neighborhoods and are merchandised with a strong line-up of necessity-based goods and services, including dominant grocers, restaurants and medical retail, as well as health, wellness and personal service uses.

Edison added, “In addition to the durable fee revenue generated, this expanded joint venture advances PECO’s capital allocation strategy by monetizing value from high-quality, stabilized assets and redeploying that capital into grocery-anchored and Everyday Retail™ opportunities with strong growth potential. PECO’s joint venture partnerships play a key role in our long-term growth and commitment to delivering stakeholder value. We’re able to do this while maintaining balance sheet strength and a disciplined approach to investing that have always defined PECO.”

The expansion will occur in stages with this initial stage seeding approximately half of the assets into the venture. Additional transfers under the existing agreement are expected to be completed by early 2027, and the timing and composition of future closings may change.

Following the completion of the expanded joint venture, PECO’s unconsolidated joint venture portfolio is expected to include more than 40 shopping centers across 17 states and will be valued at approximately $1.2 billion of assets under management.

About Northwestern Mutual

Northwestern Mutual has been helping people and businesses achieve financial security for more than 165 years. Through a comprehensive planning approach, Northwestern Mutual combines the expertise of its financial professionals with a personalized digital experience and industry-leading products to help its clients plan for what's most important. With more than $780 billion of total assets1 managed across the company's institutional portfolio as well as retail investment client portfolios, more than $40 billion in revenues, and $2.5 trillion worth of life insurance protection in force, Northwestern Mutual delivers financial security to more than five million people with life insurance, disability income insurance, long-term care insurance, annuities, and brokerage and advisory services. Northwestern Mutual ranked 109 on the 2026 FORTUNE 500 and was recognized by FORTUNE® as one of the "World's Most Admired" life insurance companies in 2026.

Learn more at https://www.northwesternmutual.com/.

Northwestern Mutual is the marketing name for The Northwestern Mutual Life Insurance Company (NM), Milwaukee, WI (life and disability insurance, annuities, and life insurance with long-term care benefits) and its subsidiaries. Subsidiaries include Northwestern Mutual Investment Services, LLC (NMIS) (investment brokerage services), broker-dealer, registered investment adviser, member FINRA and SIPC; the Northwestern Mutual Wealth Management Company® (NMWMC) (investment advisory and services), federal savings bank; and Northwestern Long Term Care Insurance Company (NLTC) (long-term care insurance). Not all Northwestern Mutual representatives are advisors. Only those representatives with "Advisor" in their title or who otherwise disclose their status as an advisor of NMWMC are credentialed as NMWMC representatives to provide investment advisory services.

1 Includes investments and separate account assets of Northwestern Mutual as well as retail investment assets held or managed for clients.

About Phillips Edison & Company
Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of June 30, 2026, PECO managed 330 shopping centers, including 302 wholly-owned centers comprising 33.9 million square feet across 31 states and 28 shopping centers owned in three institutional joint ventures. PECO is focused on creating great grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investors website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by the Company’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” “commit,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated, including the risk factors and other risks and uncertainties described in the Company’s 2025 Annual Report on Form 10-K, filed with the SEC on February 10, 2026, as updated from time to time in the Company’s periodic and/or current reports filed with the SEC, which are accessible on the SEC’s website at www.sec.gov. Except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:
Kimberly Green, Head of Investor Relations
(513) 692-3399, [email protected]

In the latest trading session, Sunrun (RUN - Free Report) closed at $7.64, marking a -1.67% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.2%. At the same time, the Dow added 0.04%, and the tech-heavy Nasdaq gained 0.04%.

Prior to today's trading, shares of the solar energy products distributor had lost 13.28% lagged the Oils-Energy sector's loss of 2.32% and the S&P 500's loss of 0.35%.

The upcoming earnings release of Sunrun will be of great interest to investors. In that report, analysts expect Sunrun to post earnings of $0.16 per share. This would mark year-over-year growth of 166.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $773.4 million, indicating a 6.74% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.19 per share and a revenue of $3.12 billion, signifying shifts of -30.41% and +5.49%, respectively, from the last year.

Investors should also pay attention to any latest changes in analyst estimates for Sunrun. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.33% rise in the Zacks Consensus EPS estimate. Sunrun is currently sporting a Zacks Rank of #3 (Hold).

Looking at valuation, Sunrun is presently trading at a Forward P/E ratio of 6.55. This expresses a discount compared to the average Forward P/E of 13.31 of its industry.

The Solar industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 212, placing it within the bottom 14% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

In the latest trading session, Eaton (ETN - Free Report) closed at $437.28, marking a +1.76% move from the previous day. This move outpaced the S&P 500's daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%.

Coming into today, shares of the power management company had gained 9.94% in the past month. In that same time, the Industrial Products sector lost 0.74%, while the S&P 500 lost 0.35%.

The upcoming earnings release of Eaton will be of great interest to investors. The company is predicted to post an EPS of $3.53, indicating a 14.98% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.42 billion, up 20.52% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.57 per share and a revenue of $32.66 billion, representing changes of +12.43% and +18.98%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Eaton. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.05% increase. Right now, Eaton possesses a Zacks Rank of #3 (Hold).

Looking at its valuation, Eaton is holding a Forward P/E ratio of 31.68. This represents a premium compared to its industry average Forward P/E of 24.08.

Investors should also note that ETN has a PEG ratio of 2.7 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Manufacturing - Electronics industry currently had an average PEG ratio of 1.62 as of yesterday's close.

The Manufacturing - Electronics industry is part of the Industrial Products sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Shares of Nu Holdings (NU +4.98%) have been volatile over the past 12 months. Their 52-week high is 69% higher than the 52-week low (as of Sept. 29). But investors should understand that the wild ups and downs are separate from how the actual business is doing. This is why it's absolutely critical to take a closer look at Nu's financial performance.

Is this fintech stock a millionaire maker?

Image source: Getty Images.

Nu's growth is the driving force Nu's historical performance provides hints of its true potential. The fundamental gains have been nothing short of phenomenal. The company's growth is the most compelling characteristic.

The business raked in $5.9 billion in revenue in Q2 (ended June 30), up 39% year over year on a currency-neutral basis, with net income rising 49%. It added 4 million net new customers during the three months, and it now has 140 million users in total. The vast majority are in Brazil, with Mexico and Colombia growing rapidly.

Management says that Nu is the largest digital banking platform in Latin America. Aided by its focus on technology and data, the company has been targeting the huge unbanked and underbanked population in the region.

Risks come from two obvious sources Deteriorating credit conditions are perhaps the biggest risk factor investors should be mindful of. Of Nu's entire $77.6 billion of credit exposure, 83% is from credit cards, a high-interest and unsecured product. In adverse economic times, customers will likely neglect these payments first.

Nu has a strong position in Latin American banking. But the countries it operates in have their own macro-related risks. Currencies are volatile. Economies are still emerging. Inflation can be a problem. And there is political corruption.

Investors who primarily allocate their capital to U.S. stocks usually don't consider these variables. But for Nu, unfavorable trends in any of these areas could derail its impressive growth story.

That said, the valuation is inviting. The stock trades at a forward price-to-earnings ratio of 14.8. At this entry point, investors might be willing to accept the risks.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

4.98

%) $

0.63

Current Price

$

13.29

The million-dollar question I believe long-term investors, particularly those looking for the potential to achieve above-normal capital appreciation, should consider Nu Holdings. As mentioned, customer, revenue, and profit growth have all been exceptional. There appears to be a sizable expansionary runway ahead as well. And as it scales up, Nu is likely developing a set of competitive strengths.

But I don't think this business has what it takes to be a millionaire maker. If you put $10,000 into the stock today, you'd need to post a monster 100-fold gain to reach the seven-figure mark. Over a 25-year time horizon, this translates to a 20% annualized rate of return. It's almost impossible to find any opportunities in the market with this kind of potential.

Nike (NKE.N) deepened its turnaround under CEO Elliott Hill, announcing a plan to shake up its operating ​model and cut more jobs after the struggling sportswear giant ‌missed analysts' expectations for quarterly revenue on Thursday.

Like many US retailers, Nike is grappling with cautious consumer spending in the face of stubborn inflation. But ​its woes have largely stemmed from strategic missteps and ​a failure to release enough new, compelling products, analysts have ⁠said, leading to an uptick in promotions and discounts. Its ​shares fell 4% in extended trading.

The company announced a new program ​to change its operating model, which includes efforts to modernize its supply chain and further reduce roles to save costs.

The program, building on its previously announced ​restructuring push, which also included job cuts, is expected to deliver ​about $2.5 billion in savings through fiscal 2031.

Nike expects its revenue to decline in ‌high-single ⁠digits in fiscal 2027. The company earlier forecast revenue to decline by a low-to-mid-single-digit percentage in the first half of fiscal 2027.

Greater China remains a weak spot for Nike, while the company also faces ​challenges in Europe

S&P ​Dow Jones Indices ⁠removed Nike from the S&P 100 (.OEX) in September as part of a quarterly rebalancing, after 18 ​years in the index of blue-chip companies.

The sportswear giant ​posted ⁠sales of $11.2 billion for the first quarter, compared with analysts' average estimate of $11.32 billion, according to data compiled by LSEG.

Its gross margin, however, ⁠rose 60 ​basis points to 42.8% in the ​quarter ended August 31, helped by lower warehousing and logistics costs.

Lyft has agreed to pay $272.5 million to settle a lawsuit accusing the ride-hailing company of violating California law by misclassifying drivers as independent contractors, instead of employees.

The company said in a regulatory filing that it believes the settlement will allow it to avoid the “costs and distraction of protracted litigation and enable management to maintain its focus on executing its business objectives.”

Lyft could not be reached for comment.

The settlement stems from a lawsuit filed by the California Labor Commissioner’s Office in August 2020 that accused Lyft of treating drivers as independent contractors rather than as employees, as required under state law at the time.

The lawsuit alleged that drivers were denied minimum wage and overtime as well as other benefits and protections provided to employees, including paid sick leave and timely wage payments.

“This settlement is about the workers who came forward and spoke up. Their voices made this outcome possible,” California Labor Commissioner Lilia García-Brower said in a statement, adding that the LCO will forgo its share of the settlement and direct those funds to drivers who filed wage claims.

The settlement, which still must be approved by a judge, covers alleged violations from April 6, 2016 to December 15, 2020 — a period California was grappling with whether workers in the booming gig economy were independent contractors or an employees.

Today, drivers for app-based transportation services like Lyft and Uber are classified as contractors after voters passed ballot measure Proposition 22 in 2020. The ballot measure provided a carve-out from Assembly Bill 5, a state law passed in 2019 that required companies like DoorDash, Lyft, and Uber to classify gig workers as employees, entitling them to minimum wage, workers’ compensation, and other benefits. 

Even after AB 5 took effect, Lyft, Uber, and other companies that relied on gig workers continued to classify their drivers as contractors. That eventually led to legal action from the LCO, California Attorney General and the City Attorneys of Los Angeles, San Diego and San Francisco, as well as private actions filed under California’s Private Attorneys General Act. The cases were coordinated in San Francisco Superior Court in September 2021.

The settlement closes this legal chapter, at least for Lyft. Uber still faces an LCO lawsuit that makes similar allegations.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Kirsten Korosec is a reporter and editor who has covered the future of transportation from EVs and autonomous vehicles to urban air mobility and in-car tech for more than a decade. She is currently the transportation editor at TechCrunch and co-host of TechCrunch’s Equity podcast. She is also co-founder and co-host of the podcast, “The Autonocast.” She previously wrote for Fortune, The Verge, Bloomberg, MIT Technology Review and CBS Interactive.

You can contact or verify outreach from Kirsten by emailing [email protected] or via encrypted message at kkorosec.07 on Signal.

Eli Lilly (LLY -0.63%) has emerged as the leader in the weight-loss market and is posting excellent financial results, partly thanks to its position in this area. And although the company will face more competition in the next few years, it will also benefit from a rapidly expanding anti-obesity market. In fact, Eli Lilly recently announced an initiative that could broaden its reach in the global weight-loss space and help it capitalize on it for years to come.

Image source: The Motley Fool.

Making weight loss drugs more accessibleOn Sept. 28, Eli Lilly announced an initiative dubbed the Lilly Change the Course Commitment. The goal is simple: Eli Lilly wants to treat as many patients with diabetes and obesity in resource-limited settings -- including low- and middle-income countries (LMICs) -- as it does in more affluent places like the U.S. before 2040. There is a massive addressable market here.

As Eli Lilly points out, roughly 70% of adults with obesity and 80% of adults with diabetes live in LMICs. Yet, there is just one adult in these countries with access to Eli Lilly's relevant medicines (which are among the world leaders) for every four adults who have access to these drugs in richer countries. Increasing access to its groundbreaking therapies could help Eli Lilly significantly expand its addressable market worldwide.

A closer look at the market opportunity One reason pharmaceutical companies tend to target richer countries is that revenue per patient in these countries is much higher than in LMICs. However, in this case, the sheer number of potential patients in other countries could more than offset that. According to the World Health Organization, as of 2022, 2.5 billion people worldwide were overweight, and 890 million of them were obese. That's several times the entire population of the U.S., never mind the number of Americans who are overweight or obese.

In addition, about 830 million people worldwide have diabetes, although there is a significant overlap between the diabetic and obese populations. Still, that's a massive worldwide addressable opportunity. Provided Eli Lilly can manufacture some of its weight-loss medicines at scale and at relatively low cost, it could tap into this large worldwide opportunity.

Premium Feature

Moneyball Superscore

92/100

Today's Change

(

-0.63

%) $

-7.23

Current Price

$

1,149.85

That's why the company's Foundayo -- its oral GLP-1 anti-obesity drug -- may become an important part of this plan. Foundayo, a small-molecule pill, could offer manufacturing and distribution advantages over Zepbound, an injectable peptide-based medication that is currently the best-selling product in this area. Even with substantially lower prices in low-income countries, Foundayo could generate meaningful sales for Eli Lilly if it achieves significant penetration in LMICs over the next decade.

What this means for Eli Lilly's prospectsAs part of its Lilly Change the Course Commitment, Eli Lilly plans to work with regulators and local health systems in LMICs, as well as with global health organizations, to train community health workers. In other words, the drugmaker could help strengthen healthcare infrastructure and build a network of connections in these countries that could outlast 2040, the year it plans to achieve its ambitious goal.

That is an important facet of this plan that investors shouldn't neglect. Eli Lilly's initiative could establish it as a more global healthcare powerhouse with a significant footprint across many LMICs, potentially giving it a competitive edge in these markets that could allow it to access more patients (perhaps including in areas outside of diabetes and weight loss) than most of its pharmaceutical peers in these countries long after 2040.

Now, it's essential to highlight that most of the company's revenue and earnings should still come from countries like the U.S. That is unlikely to change. But this initiative could materially impact the company's financial results for many years to come. There are already plenty of reasons to invest in the stock.

Eli Lilly is a leader in the weight-loss market, has a deep pipeline, has significantly diversified its portfolio in recent years, and has invested in artificial intelligence to discover and develop drugs more quickly and cheaply. This new plan is the icing on the cake.

RTX's Raytheon unit won a multiyear contract worth up to $24.4 billion to produce Standard ​Missile-6 interceptors for the US Navy, the service said on ‌Thursday, as the Pentagon pushes to replenish munitions stockpiles depleted by conflicts in the Middle East.

The five-year contract, which includes two additional option years, the Navy said, ​is meant to provide a steady and reliable supply of the ​SM-6, a missile that can carry out both offensive ⁠strikes and missile defense missions.

The SM-6 award is the latest in ​a series of large munitions contracts the Pentagon has pursued this year ​to pressure contractors into ramping up output faster. It follows a $20.7 billion provisional multiyear deal for Raytheon's AMRAAM air-to-air missiles in late September and a $58.6 billion Patriot interceptor ​deal awarded to Lockheed Martin (LMT.N) in July.

The production agreements are designed ​to entice contractors to. move faster on increasing output. They are part of a ‌broader ⁠push by the Trump administration to prioritize weapons production over shareholder returns.

Industry executives have warned that Congress has not yet appropriated funding for the deals, meaning contractors may be unable to invest at scale in ​components and facilities ​until lawmakers act.

RTX (RTX.N) ⁠has said it has invested heavily to keep up with rising demand. It has expanded its skilled ​workforce, strengthened partnerships across the defense industrial base and ​automated production, ⁠with the aim of significantly increasing output for near- and long-term needs.

Raytheon says the SM-6 is the only combat-proven weapon that can perform anti-air ⁠warfare, ​anti-surface warfare and ballistic missile defense. It ​has been fired from a range of Navy ships as well as from land-based launchers.

Fastenal Company (NASDAQ:FAST) will release earnings for its third quarter before the opening bell on Wednesday, Oct. 14.

Analysts expect the Winona, Minnesota-based company to report quarterly earnings of 34 cents per share, up from 29 cents per share in the year-ago period. The consensus estimate for FAST’s quarterly revenue is $2.44 billion. It reported $2.13 billion last year, according to Benzinga Pro.

On July 14, Fastenal reported better-than-expected second-quarter sales results.

Fastenal shares rose 0.8% to trade at $49.92 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Wolfe Research analyst Nigel Coe reinstated an Underperform rating with a price target of $51 on Sept. 15, 2026. This analyst has an accuracy rate of 63%. Morgan Stanley analyst Chris Snyder maintained an Equal-Weight rating and increased the price target from $48 to $52 on July 16, 2026. This analyst has an accuracy rate of 78%. Barclays analyst Guy Hardwick maintained the stock with an Equal-Weight rating and cut the price target from $47 to $46 on July 16, 2026. This analyst has an accuracy rate of 71%. DA Davidson analyst Chris Dankert maintained a Neutral rating with a price target of $46 on July 15, 2026. This analyst has an accuracy rate of 67%. Baird analyst David Manthey maintained the stock with an Outperform rating and cut the price target from $52 to $50 on April 14, 2026. This analyst has an accuracy rate of 73%. Considering buying FAST stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

The Hyperliquid Policy Committee has taken its lobbying show to Brussels. On October 1, 2026, the group filed its first formal submission with the European Commission, answering a consultation on how the Markets in Crypto-Assets (MiCA) framework should evolve.

The pitch is refreshingly unglamorous. Don’t write new laws, the committee argues. Use the ones Europe already has.

What the committee actually asked for The centerpiece of the filing concerns on-chain perpetual contracts, better known as perps. These are derivatives that let traders bet on an asset’s price without an expiry date. The HPC wants them brought under MiFID II, the EU’s existing rulebook for financial instruments and trading venues.

Bolting perps onto MiFID II, rather than drafting fresh legislation, is the committee’s preferred route. It also suggests the European Securities and Markets Authority (ESMA) issue guidance on how MiFID II should apply to these products.

Two principles anchor the argument: technology neutrality and economic substance. Put simply, regulators should judge a product by what it does, not by whether it runs on a blockchain or a bank server.

Advertisement

That framing matters because of what the HPC wants to avoid. Europe already places restrictions on retail access to contracts for difference, or CFDs. These are leveraged products where a trader bets on price moves, typically with a market maker on the other side of the trade.

The committee says on-chain perps work differently. They run on a public central limit order book, where buyers and sellers are matched openly rather than trading against a dealer. Because of that structural gap, the HPC argues CFD-style retail curbs should not automatically carry over to on-chain perps.

The reporting argument The filing also targets paperwork. The HPC is pushing to cut duplicate reporting obligations for data that already lives on public blockchains.

Its logic is straightforward. Public chains are open and verifiable by design, so asking firms to separately report information anyone can already inspect looks redundant.

Why the timing matters The submission lands a few months after a key MiCA deadline. The framework’s transitional period ended on July 1, 2026.

That cutoff raised the possibility of regulatory gaps for on-chain derivatives. MiCA was built largely around crypto assets and service providers, and products like perps sit awkwardly between crypto rules and traditional securities law.

The HPC’s proposal is essentially a way to close that gap without waiting years for a new legislative process. MiFID II already exists, already has supervisors, and already covers derivatives. The committee is asking Brussels to stretch it rather than start over.

Who is the Hyperliquid Policy Committee The HPC was set up in February 2026 and is funded by the Hyperliquid Foundation. It serves as the policy arm of the Hyperliquid ecosystem, which centers on decentralized trading.

Until now, its advocacy work had focused on the United States. The European filing marks its first policy submission outside the US.

The funding structure is worth keeping in mind. A policy body backed by a trading ecosystem’s foundation is, unsurprisingly, arguing for rules that would make on-chain trading easier to offer in Europe.

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.

Venture Global (VG.N) and ConocoPhillips (COP.N) said on Thursday they had signed a 20-year ​liquefied natural gas (LNG) supply agreement ‌under which ConocoPhillips will buy 1 million tonnes a year of LNG starting in 2030.

The ​deal comes as ConocoPhillips looks ​to bolster its LNG portfolio while challenges ⁠stemming from the Iran conflict have ​affected QatarEnergy's LNG operations and expansion ​projects in which ConocoPhillips holds interests.

Here are more details:

Under the agreement, ConocoPhillips will purchase 1.0 million ​tonnes a year of LNG from ​Venture Global for 20 years, with deliveries beginning ‌in ⁠2030.

Venture Global said the agreement will support ConocoPhillips' growing global LNG portfolio.

ConocoPhillips holds a 30% interest in QatarEnergy's Ras ​Laffan LNG ​project and ⁠also has stakes in LNG expansion projects in Qatar.

Venture Global ​said it has more than ​100 ⁠MTPA of LNG capacity in production, construction or development.

The company's first three LNG ⁠projects, ​Calcasieu Pass, Plaquemines LNG ​and CP2 LNG, are located in Louisiana.

Bitcoin O.G. Peter Todd has joined the MARA Foundation as lead maintainer of Slipstream, the miner’s private Bitcoin mempool service. 

Announced by the foundation on Thursday, the new role will see Todd responsible for developing and running the service.

Slipstream lets users send bitcoin transactions straight to MARA Pool, the company’s mining pool, without going through Bitcoin’s public peer-to-peer network. It was useful after hackers exploited Coldcard hardware wallets in July, stealing over $115 million in user funds. 

Because transactions sent through Slipstream stay private until they’re confirmed in a block, the service helps to keep key information hidden before confirmation — protecting exposure of their public keys. 

“I most look forward to seeing what’s possible on Bitcoin — using Slipstream as a proving ground for experimental development and protocol innovation,” Todd said. 

Todd added: “Working with Slipstream is a natural complement to my work on Libre Relay, and my mempool policy work more broadly. I’ve always believed that Bitcoin is better when we design protocols with economic demand in mind. This is also a good opportunity to build bridges between Bitcoin Core developers and miners.”

MARA’s Slipstream first drew attention in 2024 for publishing large Ordinals inscriptions. More recently it has been used for research projects like Quantum Safe Bitcoin and Binohash, a way to emulate covenants without a soft fork.

Todd is a longtime Bitcoin Core contributor, who co-authored BIP 125 (replace-by-fee), created OpenTimestamps, and in 2024 launched Libre Relay, a Bitcoin Core fork with looser relay rules for non-standard transactions. 

He argues that mempool policy should follow what the market wants miners to mine, rather than restrict how people use Bitcoin.

Mathew Di Salvo

Mathew is a reporter who's covered the space since 2019, reporting on everything from Salvadoran president Nayib Bukele's Bitcoin bet to crypto exchange FTX's bankruptcy.

Greywick Digital (@Greywickdigital) and the Litecoin Foundation (@LTCFoundation) have signed a Memorandum of Understanding to bring $cLTC, a Canton-native version of $LTC, to the @CantonNetwork. The agreement targets a live deployment before the end of 2026, opening one of crypto's oldest proof-of-work networks to institutional-grade finance infrastructure.

What cLTC Is and How It Will Work

Each cLTC token will operate under on-chain reserve validation, continuous attestations, and built-in compliance mechanisms, preserving the auditability that institutional participants require. The structure is designed to link $LTC's more than 15 years of network history to Canton's regulated multi-party settlement environment.

Why Canton Matters for Institutions

That puts $LTC liquidity into an environment where,

The move reflects a broader trend of connecting established crypto assets to regulated financial rails. Canton's privacy-first design means counterparties see only the transaction data relevant to them, a feature that has helped attract Tier-1 institutions that are cautious about exposing proprietary flow on fully public ledgers. For Litecoin, the partnership represents a concrete institutional use case at a moment when many legacy crypto assets are searching for fresh relevance beyond retail trading.

Sources:
TechBullion: Greywick Digital to Deploy cLTC on Canton Network
Canton Network: DTCC and Digital Asset Partner to Tokenize US Treasury Securities

The co-authors of EIP-8363, a proposal to burn a rising share of Ethereum validator rewards as more Ethereum (ETH) is staked, have withdrawn it from consideration for the network's Hegota upgrade. 

"Withdrawing EIP-8363 from consideration for Hegotá," co-author Jérôme de Tychey, president of Ethereum France, wrote in an X post on Thursday morning.

De Tychey said several industry participants, as well as core protocol and client contributors, argued during Hegotá's Consideration for Inclusion (CFI) process that "a fork scoping exercise was not the right venue to settle an issuance policy change."

"We agree and we'd rather acknowledge this now than carry on towards Hegotà in this context," he wrote, noting that the proposal had become "one of the most commented-on EIPs in the history of the Ethereum-Magicians forum." 

The authors committed to a separate process for determining questions of Ethereum's issuance policy. De Tychey thanked liquid staking protocol Lido for offering to help steer it.

A separate, dedicated process De Tychey grouped the objections raised since August into five categories: security, industry impact, the design of the burn curve, the makeup of the validator set and the effect on solo stakers.

To determine how to proceed with tackling the issues, de Tychey attached a timeline for what he called a "multi-node process." It starts with an issuance forum at Devcon in November, following a first roundtable at EthCC 2026.

Workshops would follow after Devcon and in February and March, with a tentative forum at a Columbia University cryptoeconomics workshop in January.

The schedule ends with a forum at EthCC in April, where the authors aim to engage core developers and reach CFI or Scheduled for Inclusion (SFI) status for a proposal.

De Tychey said the authors stand by the proposal's motivation. He quoted the EIP's view that a very high staking ratio threatens "Ethereum's security, neutrality and resistance to capture" as well as "ETH's role as money."

The proposal Researchers including the Ethereum Foundation's Justin Drake, Pintail, de Tychey, dapplion, pa7x1 and Ladislaus von Daniels proposed the "Tapered Issuance Burn" on Aug. 4, days before Hegota's deadline for non-headliner EIPs.

Under the EIP, the share of rewards burned would climb with the total level of staked ETH and would reach 100% at about 60.25 million ETH, or roughly half of the supply. The change would phase in over about 18 months.

About 34% of ETH supply was staked in mid-August, The Block reported at the time. At that level, annual consensus yield would fall from about 2.6% to 1.2% under the proposal.

Industry reaction SharpLink CEO Joseph Chalom formally opposed the proposal in August, saying it would "undermine DeFi." Aave founder Stani Kulechov called it "hurtful for Ethereum" at the time.

On Thursday, Kulechov quote-posted de Tychey's announcement of the withdrawal, saying "Great move."

Developers are still scoping Hegota, an upcoming Ethereum hard fork, which will follow the next update, Glamsterdam. On Sunday, Ethereum co-founder Vitalik Buterin outlined his vision for the future of Ethereum in a blog post, and said Hegota "is likely to be Ethereum's last 'normal' fork, with features and technology that would be recognizable to someone in 2015."

"Everything after that involves recursive STARKs, automated formal verification, highly optimized consensus algorithms, and making it all quantum-safe," Buterin wrote.